Reverb Therapeutics has joined hands with Royalmount Laboratories, as Reverb works towards lead selection and pre-IND enabling work on its first drug candidate.

Royalmount Laboratories is one of Canada’s premier CRO organizations, supporting biopharma and pharma companies with their bioanalytical needs to advance their discovery, preclinical, and clinical programs. It is rapidly becoming the leading niche small and large molecule bioanalytical CRO in Canada.

“As we move towards the start of clinical trials in about 18 months, we needed a scientific partner that could assist with toxicity studies, scale-up of manufacturing, and a variety of CMC tasks to ensure that our drug candidate moves swiftly from the lab to the clinic. We are impressed with Royalmount Laboratories’ capabilities and the quality of their staff,” said David de Graaf, Ph.D., CEO of Reverb Therapeutics.

Adrien Musuku, Senior Director of Biopharmaceutics for Royalmount Laboratories, said, “At Royalmount Laboratories, we provide both small and large molecule bioanalytical support needed to bring life-changing therapies to those in need. Our proven track record of strong science, unmatched quality and consistent on-time delivery facilitates quick advancement in the development of new therapeutic entities. We are proud to support companies like Reverb Therapeutics, an early-stage firm with novel science and a unique approach to harnessing the power of cytokines to treat disease. Reverb Therapeutics is a perfect example of the kind of dynamic company we want to help advance to the clinic and beyond.”

Reverb’s novel Amplify•R™ platform combines bispecific antibody engineering with data-driven modelling of antibody-tissue interaction to amplify endogenous cytokines and redirect them to tissues of interest.

This approach avoids the hurdles that have blocked other attempts to enlist cytokines to treat disease, which include systemic toxicity, immunogenicity, and manufacturing issues. Reverb Therapeutics is developing its precision medicine for the immune system with a focus on the treatment of cancer and auto-immune diseases.

The Amplify•R platform is designed to expand the therapeutic window of cytokines by harnessing the body’s endogenous cytokines and amplifying their activity in a tissue-specific manner, leading to profound disease-modifying effects.

The Amplify•R platform is a modular, plug-and-play, IgG-based platform, enabling rapid pre-clinical testing and ease of manufacturing for scale-up and clinical utility.